Herrstedt, J., Roila, F., Warr, D., Celio, L., Navari, R., Hesketh, P., . . . Aapro, M.S. (2017). 2016 updated MASCC/ESMO consensus recommendations: Prevention of nausea and vomiting following high emetic risk chemotherapy. Supportive Care in Cancer, 25, 277–288.
RESOURCE TYPE: Evidence-based guideline
PHASE OF CARE: Active antitumor treatment
One thousand three hundred and thirty articles were initially retrieved, and a final set of 22 were used for the update.
Very few studies examining olanzapine were included. More evidence is available.
This review provides guidelines regarding prophylaxis for acute and delayed CINV for patients receiving HEC or AC-based chemotherapy. Recommendations are consistent with those of other professional groups. This review does not include the consideration of dexamethasone-sparing regimens and does not include the full range of olanzapine-based regimen evidence.